Roquefort Therapeutics PLC Midkine Antibody Program - Festival of Biologics
October 25 2022 - 2:00AM
RNS Non-Regulatory
TIDMROQ
Roquefort Therapeutics PLC
25 October 2022
25 October 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Presentation of Midkine Antibody Program Update at the Festival
of Biologics Conference
Abstract accepted at leading biological therapeutics
conference
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class
medicines in the high value and high growth oncology market , is
pleased to announce that its Midkine antibody program update will
be presented on 3 November 2022 at the Festival of Biologics
conference in Basel, Switzerland. The ROQA1 (CAB 102) and ROQA2
(CAB101) programs have demonstrated efficacy in validated in vivo
models of breast cancer and osteosarcoma resulting in a
significantly reduced metastatic index (P<0.05), safety in
rodent and non-human primates toxicology studies, and scalable
production of CAB102.
The poster is embargoed until the presentation at the conference
but will then be available at the Roquefort Therapeutics
website.
The title of the presentation poster and presenter details will
be published on the conference website today:
https://www.terrapinn.com/conference/festival-of-biologics/Posters.stm
-Ends-
Enquiries:
Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan +44 (0)20 3918
Reginald (CEO) 8633
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of four best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- MK cell therapy with direct and NK-mediated anti-cancer action; and
-- siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPGRWUUPPGQC
(END) Dow Jones Newswires
October 25, 2022 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024